InterVene has raised $15 million in a Series B financing round for the development of its venous valve repair device.

The funding round was led by new investor 3×5 Partners. Other participants included prior investors RiverVest Venture Partners, Boston Scientific Corporation and Correlation Ventures among others.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company’s catheter-based BlueLeaf Endovenous Valve Formation System for deep vein reflux (DVR) does not require an implant.

InterVene CEO Fletcher Wilson said: “The funds will be utilised to expand our clinical research programme abroad, and to initiate trials in the US via an Investigational Device Exemption study.”

“We expect to further demonstrate safety and clinical effectiveness while we optimise the BlueLeaf System and procedure in preparation for a subsequent pivotal study.”

The company noted that its BlueLeaf System has been designed to address severe chronic venous insufficiency (CVI) due to DVR by forming new vein valves for patients without the need for an implant.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A physician can use the system to develop new valves from the inner layer of the vein wall. This will result in ‘autogenous’ valves, which aim to reduce retrograde blood flow and lessen the symptoms associated with elevated venous pressures.

The BlueLeaf technique, which is predicated on the Maleti Neovalve open-surgical procedure, enables patients to avoid the trauma of open surgery.

Additionally, it allows the formation of multiple valves in a single procedure and mechanises certain aspects of the open surgery.

Approximately 6.5 million Americans suffer from DVR which involves the failure of venous valves in the legs and can lead to poor blood flow back to the heart and the formation of blood in the legs.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact